Citryll Secures EUR 85M Series B for NET-Targeting Therapy in Inflammatory Disorders

Citryll has successfully closed an oversubscribed EUR 85 million Series B funding round to advance its innovative treatment for immune-mediated inflammatory disorders. The funding, co-led by Johnson & Johnson Innovation – JJDC, Inc., Forbion, and Novartis Venture Fund, will support the clinical progression of CIT-013, a novel monoclonal antibody.

CIT-013 targets Neutrophil Extracellular Traps (NETs), web-like structures released by neutrophils during immune responses. Though NETs play a role in trapping and destroying pathogens, their excessive formation can lead to tissue damage and chronic inflammation. Citryll's therapeutic approach aims to clear existing NETs and prevent the formation of new ones, addressing a vital aspect of the inflammatory process that current therapies do not.

The company recently concluded its first-in-human Phase 1 trials, which included successful repeat dosing in rheumatoid arthritis (RA) patients. The forthcoming Phase 2a trials will focus on RA and hidradenitis suppurativa (HS), demonstrating CIT-013's dual mechanism of action. This monoclonal antibody is designed to selectively bind to its target without penetrating cells, thereby reducing off-target effects and preserving normal cellular functions.

The new funding will enable Citryll to further develop CIT-013, with a vision of applying its NET-targeting approach to a broad range of immune-mediated inflammatory diseases. The company’s innovative strategy has the potential to provide more effective treatment options for conditions that have limited therapeutic success currently.

Following the Series B round, new representatives from Forbion, Novartis Venture Fund, and JJDC will join Citryll’s Board as non-executive directors. Geert-Jan Mulder of Forbion expressed optimism about Citryll's advancements, highlighting the promise of NET-targeting therapy in addressing unmet needs in inflammatory diseases like RA and HS.

Eduardo Bravo, CEO of Citryll, emphasized the significance of securing funding from a diverse group of global investors who share the company's enthusiasm for CIT-013’s potential. He acknowledged the foundational work of the company’s founders and expressed excitement about the clinical trials' future steps.

Citryll is at the forefront of developing a transformative approach to treating inflammatory diseases by focusing on NETs. Its lead product, CIT-013, aims to provide a comprehensive and effective treatment option for patients who struggle with inadequate disease control from current therapies.